"Organovo (ONVO) and Novavax (NVAX) are two junior biotech companies that have performed very well in 2013, besting the S&P 500's gains by a wide margin. However, these company's fundamentals and the story behind them are quite disparate. Going forward, Novavax has meaningful foreseeable catalysts and good fundamental reasons to stretch its gains further in 2014 while the opposite is true for Organovo."
LONDON (Reuters) - Scientists have found that a mutation in a new strain of bird flu infecting people in China can render it resistant to a key first-line treatment drug without limiting its ability to spread in mammals.
The discovery means that unlike seasonal flu strains, which often become less transmissible when they develop resistance to drugs like Roche's Tamiflu, the new H7N9 bird flu does not lose any of its spreading potential with drug resistance.
While this does not make H7N9 any more likely to develop into a human pandemic, researchers said it means doctors should be prudent in their use of anti-viral medicines to treat H7N9 cases, and consider using drugs other than Tamiflu, such as GlaxoSmithKline's Relenza, where possible.
"It's important to emphasise that these H7N9 viruses seem to transmit fairly inefficiently overall," said Nicole Bouvier, who led the H7N9 study which was published in the journal Nature Communications on Tuesday.
"But what was surprising about our study was that the drug-resistant virus was no less efficient than the drug-sensitive one. Usually what we see with influenza, is that resistance...also confers a fitness disadvantage on the virus."
H7N9 bird flu emerged earlier this year in China and has infected at least 139 people so far in China, Taiwan and Hong Kong, killing 45 of them.
Experts say there is no evidence as yet of any easy or sustained human-to-human transmission of H7N9. But an early scientific analysis of probable transmission of the new flu from person to person, published in August, gave the strongest proof yet that it can at times jump between people and so could potentially cause a human pandemic.
A separate team of researchers in the United States said this week that while it is not impossible that H7N9 could become easily transmissible from person to person, it would need to undergo multiple mutations to do that. So scientists around the world are keeping a watchful eye, on alert for any sign the virus m
at $4.2535... among a scattering of under $4.20 small lots
Sellers must be about phased out by now, considering selling most of the day yesterday and today...
A smidgeon of news would be nice..
they'd like to deceive us... lololol
This speaks loudly about the investor mentality currently. Seller remains weak versus buyer. Volume above average today, once again. The shares available in the float are reduced by fund buying.. as they are more long term than trading.
No inside buying lately? This fact may exist because they have information which the public does not have concerning the fundamentals of the company. They may know that something is underway regarding partnering... or trial results... or buyout offers... etc...
New England Journal article due on the 26th... a December plus. Early results on the 720 subject RSV trials may be just ahead as it has been close to two months since inception. Perhaps January on that.
Interestingly.. no upcoming events are listed on the web site... however... they are very lax about keeping the site up to day. The current RSV trial is not even listed under clinical trials. Website updating is a sore point with me. They have to update the PATH page, for example. And the LSG (Korea) page. Evidently, the web site is not high on the list of things to do.. A manager or two have to do the writing and.. they are busy improving vital aspects of the company..
All in all.. everything looks pretty darn good for investors.. can't think of any vital negatives.
1) Hire CFO - CHECK
2) Good RSV Phase 1 top line Elderly results - CHECK
3) Good preclinical data for H7N9 (Phase 1 Trial) - CHECK
4) Close of Isconova public offer - CHECK
5) Completion of RSV Phase IIa for women - CHECK
6) Completed process optimization with excellent yield and quality improvements (Sep. 24) - CHECK
7) Starting of RSV Phase IIb trial for women - CHECK
8) Extension of PATH partnership (Part 1)
9) Completion of RSV Phase 1 trial for Elderly
10) Good preclinical data for MERS (Prelim Data to NIH/Saudi, Phase 1?)
11) Good H7N9 Phase 1 top line results
---------------------------------------------------------------------- 2014 is below
11) Collection of $3MM from seasonal flu IND
12) Possible new BARDA contract or NIH funding for MERS
13) Starting of Quad Seasonal Flu phase 2b trial
14) Starting RSV/Flu combo "Respiratory Vaccine" Phase 1 trial
15) Completion of H7N9 Phase 1 trial
16) Starting of Pandemic H7N9 flu w/ Matrix M phase 2 trial for adult
17) Starting of Pandemic H7N9 flu w/ MM phase 2 trial for elderly
18) Completion of RSV Phase IIb trial for women
19) Completion of RSV reproductive toxicity study
20) Starting RSV Pediatrics Phase 1 trial
21) Starting RSV in pregnant women Phase 2b trial
22) Extension of PATH partnership (Part 2)
23) Completion of Seasonal flu Phase 2b trial
24) Good Pandemic H7N9 flu Phase 2 trial top line data
25) BARDA picks up 2nd half of contract
26) Starting Seasonal flu vaccine Phase III
27) Rabies Phase 1 in India
28) Trivalent Seasonal Flu Phase 2 in India
29) Good preclinical data for Malaria or FMD
30) "Partners" and Matrix M results
31) Stockpile Order Ja
if the close is green at all... it will be the 7th consecutive day of green closing... today so far is a mild relaxation in the midst of a string of numerous green days to come.... looking for $5-6 by year end.
do you mean this: "FBR sees huge upside for Novavax on RSV vaccine potential
Novavax (NVAX +8.3%) is up sharply in morning trading.Helping the cause is FBR's William Tanner, who calls the company "one of the mos compelling small-cap vaccine plays in the biopharma sector by virtue of the vaccine for preventing RSV infection."Although Tanner thinks absence of visibility into stockpiling plans makes it "difficult to ascribe much value" to NVAX's pandemic vaccine programs, he says that "if safe and effective, the [RSV] vaccine could have broad utility for preventing infection in pregnant women, neonates (by virtue of maternal vaccination), infants, and young children and the elderly."Shares initiated at Outperform.Price target is $11"
that's interesting... so.. Evans 750k (est) share may soon pay off...
I can find only one reason to disagree with noguts... ie.. no one should sell one tiny share until at least $11/share... Otherwise, he is highly reasonable and instructional...
slow... yes... lol... they all are including the God assumption.
jens... If you don't kiss my ring, darn it, I going to feel hurt. Sorry I hurt your feelings regarding using technical, graphy, type guides. I don't buy them for this stock but... I should regard them since X people use them for trading. So.. there is validity. I just don't care for traders who, one day are quite positive and the next day they are negative... playing us all, for some reason, to facilitate their system trades. These posting traders are hypocritical, in my opinion. They post their ins and outs for one reason... to influence other posters to follow their game. I post to reveal the positives in the Novavax company. If there are negatives (there are not) then all you trader folks (and short folks) will furnish that information. I need not abet them.
bball.. when someone says he's changing his trade buy from $3.90 to $3.20... that's a very distinct message to investors. Why would you think it anything but a statement of negativity intended to change minds? Everything he said was reasonable, but when he said that... well.. it spoke volumes of this intentions. He set it up on a long post, positing his ethical reasons for taking profit. Who broadcasts a sell, anyway? why?